XML 39 R20.htm IDEA: XBRL DOCUMENT
v3.21.1

Equity Incentive Plan | 12 Months Ended
--- | ---
Dec. 31, 2020
Share-based Payment Arrangement [Abstract] |
Equity Incentive Plan | Note 14 – Equity Incentive Plan On August 1, 2017, the Board adopted and approved the Company’s 2017 Equity Incentive Plan (the “2017 Equity Plan”) in order to attract, motivate, retain, and reward high-quality executives and other employees, officers, directors, consultants, and other persons who provide services to the Company by enabling such persons to acquire an equity interest in the Company. Under the 2017 Equity Plan, the Board (or the compensation committee of the Board, if one is established) may award stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted stock unit awards (“RSUs”), shares granted as a bonus or in lieu of another award, and other stock-based performance awards. The 2017 Equity Plan allocates 50,000,000 shares of the Company’s common stock (“Plan Shares”) for issuance of equity awards under the 2017 Equity Plan. As of December 31, 2020, the Company has granted, under the 2017 Equity Plan, awards in the form of RSAs for services rendered by independent directors and consultants, non-qualified stock options, RSUs and stock bonus awards. The total unrecognized compensation expense for unvested non-qualified stock options at December 31, 2020 was $6,412, which will be recognized over approximately 3 months. Restricted Stock Awards As of December 31, 2018, the Company had accrued fees owed to the Company’s independent directors totaling $15,000, which were payable in equity. During the year ended December 31, 2019, the Company issued 197,370 shares of restricted stock, which were fully vested at the time of the award, in settlement of these accrued fees. During the year ended December 31, 2019, the Company also awarded 789,474 shares of restricted stock under the 2017 Equity Plan to the Company’s independent directors and consultants as an equity retainer fee for 2019. These restricted shares were fully vested at the time of the award and the aggregate value attributable to these shares was $60,000, as calculated using the fair value of the Company’s common stock on date the Board approved these awards. Non-Qualified Stock Options The Company uses the Black-Scholes Model to determine the fair value of options granted. Option-pricing models require the input of highly subjective assumptions, particularly for the expected stock price volatility and the expected term of options. Changes in the subjective input assumptions can materially affect the fair value estimate. The expected stock price volatility assumptions are based on the historical volatility of the Company’s common stock over periods that are similar to the expected terms of grants and other relevant factors. The Company derives the expected term based on an average of the contract term and the vesting period taking into consideration the vesting schedules and future employee behavior with regard to option exercise. The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected term calculated at the date of grant. The Company has never paid any cash dividends on its common stock and the Company has no intention to pay a dividend at this time; therefore, the Company assumes that no dividends will be paid over the expected terms of option awards. The Company determines the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at those grant dates. As such, the Company may use different assumptions for options granted throughout the year. The valuation assumptions used to determine the fair value of each option award on the date of grant were: expected stock price volatility 114.97% - 122.48%; expected term in 5 years and risk-free interest rate 0.2% - 2.37%. Employee and Consultant Options A summary of the non-qualified stock options granted to employees and consultants under the 2017 Equity Plan during the years ended December 31, 2020 and 2019 are presented in the table below:
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value |
Outstanding, December 31, 2018 |  |  | 10,560,000 |  |  | $ | 0.104 |  |  |  | 8.4 |  |  | $ | - |
Granted |  |  | 2,000,000 |  |  | $ | 0.080 |  |  |  |  |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Forfeited |  |  | (2,408,333 | ) |  | $ | 0.116 |  |  |  |  |  |  |  |  |
Expired |  |  | (16,667 | ) |  | $ | 0.105 |  |  |  |  |  |  |  |  |
Outstanding, December 31, 2019 |  |  | 10,135,000 |  |  | $ | 0.096 |  |  |  | 7.7 |  |  | $ | - |
Granted |  |  | 6,616,900 |  |  | $ | 0.070 |  |  |  | 10.0 |  |  |  |  |
Exercised |  |  | - |  |  |  |  |  |  |  |  |  |  |  |  |
Forfeited |  |  | - |  |  |  |  |  |  |  |  |  |  |  |  |
Expired |  |  | (2,500,900 | ) |  | $ | 0.101 |  |  |  | 4.3 |  |  |  |  |
Outstanding, December 31, 2020 |  |  | 14,251,000 |  |  | $ | 0.083 |  |  |  | 8.3 |  |  | $ | - |
Exercisable, December 31, 2020 |  |  | 14,251,000 |  |  | $ | 0.083 |  |  |  | 8.3 |  |  | $ | - |
A summary of non-vested non-qualified stock options activity for employees and consultants under the 2017 Equity Plan for the years ended December 31, 2020 and 2019 are presented in the table below:
﻿ |  | Number of Options |  |  | Weighted Average Grant-Date Fair Value |  |  | Aggregate Intrinsic Value |  |  | Grant-Date Fair Value |
﻿ |  |  |  |  |  |  |  |  |  |  |  |
Nonvested, December 31, 2018 |  |  | 7,333,329 |  |  | $ | 0.086 |  |  | $ | - |  |  | $ | 628,756 |
Granted |  |  | 2,000,000 |  |  | $ | 0.065 |  |  |  |  |  |  | $ | 130,120 |
Vested |  |  | (4,924,996 | ) |  | $ | 0.074 |  |  |  |  |  |  | $ | 362,998 |
Forfeited |  |  | (2,408,333 | ) |  | $ | 0.102 |  |  |  |  |  |  | $ | 246,344 |
Expired |  |  | - |  |  |  | - |  |  |  |  |  |  | $ | - |
Nonvested, December 31, 2019 |  |  | 2,000,000 |  |  | $ | 0.075 |  |  | $ | - |  |  | $ | 149,534 |
Granted |  |  | 6,616,900 |  |  | $ | 0.059 |  |  |  |  |  |  | $ | 387,199 |
Vested |  |  | (8,616,900 | ) |  | $ | 0.062 |  |  |  |  |  |  | $ | 536,733 |
Forfeited |  |  | - |  |  |  |  |  |  |  |  |  |  | $ | - |
Expired |  |  | - |  |  |  |  |  |  |  |  |  |  | $ | - |
Nonvested, December 31, 2020 |  |  | - |  |  |  |  |  |  | $ | - |  |  | $ | - |
For the years ended December 31, 2020 and 2019, the Company recorded $189,568 and $390,485 as compensation expense related to vested options issued to employees and consultants, net of forfeitures, respectively. As of December 31, 2020, there was no unrecognized share-based compensation related to unvested options. As of December 31, 2020, the Company had granted non-qualified options to purchase 10,250,000 shares which were performance-based. At December 31, 2020, non-qualified options to purchase 6,000,000 shares were forfeited due to the failure to satisfy the 2017, 2018 and 2019 revenue-based performance thresholds and 4,250,000 shares were forfeited due to employee terminations. No compensation expense had been recognized with respect to these performance-based awards since the likelihood of performance levels being obtained was determined to be remote. Director Options A summary of the non-qualified stock options granted to directors under the 2017 Equity Plan during the years ended December 31, 2020 and 2019 are presented in the table below:
|  | Number of Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value ($000) |
Outstanding, December 31, 2018 |  |  | 900,000 |  |  | $ | 0.135 |  |  |  | 8.6 |  |  | $ | - |
Granted |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Forfeited/Cancelled |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Expired |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Outstanding, December 31, 2019 |  |  | 900,000 |  |  | $ | 0.135 |  |  |  | 7.6 |  |  | $ | - |
Granted |  |  | 6,500,000 |  |  | $ | 0.057 |  |  |  | 8.5 |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Forfeited/Cancelled |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Expired |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Outstanding, December 31, 2020 |  |  | 7,400,000 |  |  | $ | 0.067 |  |  |  | 7.5 |  |  | $ | - |
Exerciseable, December 31, 2020 |  |  | 6,400,000 |  |  | $ | 0.073 |  |  |  | 8.0 |  |  | $ | - |
A summary of non-vested non-qualified stock options activity for directors under the 2017 Equity Plan for the years ended December 31, 2020 and 2019 are presented in the table below:
﻿ |  | Number of Options |  |  | Weighted Average Grant-Date Fair Value |  |  | Aggregate Intrinsic Value |  |  | Grant-Date Fair Value |
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonvested, December 31, 2019 |  |  | - |  |  |  | - |  |  | $ | - |  |  |  |  |
Granted |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Vested |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Forfeited |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Expired |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Nonvested, December 31, 2019 |  |  | - |  |  |  | - |  |  | $ | - |  |  |  |  |
Granted |  |  | 6,500,000 |  |  |  | 0.057 |  |  |  |  |  |  | $ | 373,000 |
Vested |  |  | (5,500,000 | ) |  |  | 0.063 |  |  |  |  |  |  | $ | 344,000 |
Forfeited |  |  | - |  |  |  | - |  |  |  |  |  |  | $ | - |
Expired |  |  | - |  |  |  | - |  |  |  |  |  |  | $ | - |
Nonvested, December 31, 2020 |  |  | 1,000,000 |  |  |  | 0.029 |  |  | $ | 5,800 |  |  | $ | 29,000 |
During the years ended December 31, 2020 and 2019, the Company incurred $62,452 and $0, respectively, as compensation expense related to 1,500,000 and 0 vested options, respectively, issued to directors. As of December 31, 2020, total unrecognized share-based compensation related to unvested options was $6,412. Effective January 2, 2020, the Company issued 4,000,000 fully vested stock options to directors valued at $234,126 in respect of a 2019 special equity award that had been accrued for in full in the Company’s financial statements at December 31, 2019. Further on January 2, 2020, the Company issued an additional 500,000 fully vested, non-qualified stock options under the 2017 Equity Plan valued at $29,266 to directors. The options have a term of 5 years and have an exercise price equal to the closing price of the Company’s common stock on The OTC Markets on the day immediately preceding the grant date of $0.07. Effective June 24, 2020, the Company issued 2,000,000 non-qualified stock options under the 2017 Equity Plan, valued at $39,600, to newly appointed directors. The options vested 50% upon grant and 50% on April 1, 2021, if the Director remains on the Board up to that time. The options have a term of 5 years and have an exercise price equal to the closing price of the Company’s common stock on The OTC Markets on the day immediately preceding the grant date of $0.029. As of December 31, 2020, awards related to 21,651,000 shares remain issued and outstanding. Restricted Stock Units A summary of the RSUs awarded to employees, directors and consultants under the 2017 Equity Plan during the years ended December 31, 2020 and 2019 are presented in the table below:
|  | Number of Units |  |  | Weighted Average Grant-Date Fair Value |  |  | Aggregate Intrinsic Value |
Outstanding, December 31, 2018 |  |  | 9,867,368 |  |  | $ | 0.140 |  |  | $ | 730,185 |
Granted |  |  | - |  |  |  | - |  |  |  |  |
Vested and settled with share issuance |  |  | (1,120,000 | ) |  | $ | 0.181 |  |  |  |  |
Forfeited/canceled |  |  | (1,197,368 | ) |  | $ | 0.179 |  |  |  |  |
Outstanding, December 31, 2019 |  |  | 7,550,000 |  |  | $ | 0.128 |  |  | $ | - |
Granted |  |  | - |  |  |  | - |  |  |  |  |
Vested and settled with share issuance |  |  | (6,750,000 | ) |  | $ | 0.121 |  |  |  |  |
Forfeited/canceled |  |  | (800,000 | ) |  | $ | 0.184 |  |  |  |  |
Outstanding, December 31, 2020 |  |  | - |  |  |  |  |  |  | $ | - |
For the years ended December 31, 2020 and 2019, the Company recorded $25,163 and $278,906 as compensation expense related to vested RSUs issued to employees, directors and consultants. As of December 31, 2020, there was no unrecognized share-based compensation related to unvested RSUs. The total intrinsic value of RSUs vested and settled with share issuance was $199,125 and $79,120 for the years ended December 31, 2020 and 2019. During the year ended December 31, 2020, the total intrinsic value of RSUs vested and settled with share issuance was $1,105,750, including the intrinsic value of $1,035,750 related to RSUs that had vested in 2018 but had not been settled until 2020 due to a dispute with a former employee over the required withholding taxes to be paid to the Company for remittance to the appropriate tax authorities as further discussed in Note 11 Commitments and Contingencies above. Effective April 30, 2020, 800,000 RSUs vested. However, the holder elected to cancel the RSUs. Incentive Stock Bonuses The Company has entered into certain “at-will” employment agreements with certain employees. Under these agreements, the employees are eligible to receive special incentive stock bonuses, provided the Board has determined, in its sole discretion, that the employee’s performance has been average or better for the applicable special bonus period. This special stock incentive bonus is payable only if the employee continues in the employment of the Company. For accounting purposes, the Company treats these special incentive stock bonuses as vesting over each bonus’s service period based on the fair value of the award at the time of grant. Even though these bonuses are subject to Board approval, the awards are vested over each service period because it is more likely than not that the Board will approve the award based on the “average or better” employee performance standard. Since the awards are denominated in shares of common stock, the fair value of the vested bonus is charged to additional paid-in capital. A summary of the incentive stock bonus awards granted to employees under the 2017 Equity Plan during the years ended December 31, 2020 and 2019 are presented in the table below:
|  | Number of Shares |  |  | Weighted Average Grant-Date Fair Value |  |  | Aggregate Intrinsic Value |
﻿ |  |  |  |  |  |  |  |  |  |  |  |
Unvested, December 31, 2018 |  |  | 1,680,000 |  |  | $ | 0.112 |  |  | $ | 124,320 |
Awarded |  |  | - |  |  |  | - |  |  |  |  |
Vested |  |  | (1,680,000 | ) |  | $ | 0.112 |  |  |  |  |
Forfeited |  |  | - |  |  |  | - |  |  |  |  |
Unvested, December 31, 2019 |  |  | - |  |  |  | - |  |  |  |  |
Awarded |  |  | - |  |  |  | - |  |  |  |  |
Vested |  |  | - |  |  |  | - |  |  |  |  |
Forfeited |  |  | - |  |  |  | - |  |  |  |  |
Unvested, December 31, 2020 |  |  | - |  |  |  | - |  |  |  |  |
For the years ended December 31, 2020 and 2019, the Company recorded $0 and $44,209 as compensation expense related to vested stock bonus awards issued to employees, net of forfeitures of $0 and $0, respectively. As of December 31, 2020, there was no unrecognized share-based compensation related to unvested stock bonus awards. The total intrinsic value of stock bonus awards vested and settled with share issuance was $0 and $58,240 for the years ended December 31, 2020 and 2019, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration